Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna Therapeutics' miv-cel therapy demonstrates durable clinical benefit and a favorable safety profile in patients with stiff person syndrome and progressive multiple sclerosis. The treatment achieved significant improvements in walking performance and disability, with a median 49% improvement in walking ability at one year. This contrasts with safety concerns in the broader autoimmune CAR-T field, including Novartis trial setbacks.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year
- ✓ Nearly all patients remained off chronic immunotherapies after treatment with miv-cel
- ✓ Miv-cel delivered a 49% median improvement in walking performance among patients with stiff person syndrome
- ✓ The safety profile of miv-cel lacks high-grade cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or immune effector cell-associated hemophagocytic lymphohistiocytosis
What changed
Kyverna Therapeutics presented one-year data from its KYSA-8 registrational trial for stiff person syndrome and updated Phase 1 data for progressive multiple sclerosis, demonstrating sustained clinical benefit and a favorable safety profile.
Live updates
-
Kyverna's miv-cel shows sustained benefit in autoimmune diseases
Kyverna Therapeutics' miv-cel therapy demonstrates durable clinical benefit and a favorable safety profile in patients with stiff person syndrome and progressive multiple sclerosis. The treatment achieved significant improvements in walking performance and disability, with a median 49% improvement in walking ability at one year. This contrasts with safety concerns in the broader autoimmune CAR-T field, including Novartis trial setbacks.
Why it matters
Kyverna's progress is notable amid challenges in the autoimmune CAR-T therapy space. The company's therapy, miv-cel, has shown promise in treating severe autoimmune diseases, including stiff person syndrome and progressive multiple sclerosis. The therapy's safety profile and efficacy have been highlighted in recent presentations at the MS Toronto 2026 conference.
What is confirmed
- Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year
- Nearly all patients remained off chronic immunotherapies after treatment with miv-cel
- Miv-cel delivered a 49% median improvement in walking performance among patients with stiff person syndrome
- The safety profile of miv-cel lacks high-grade cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or immune effector cell-associated hemophagocytic lymphohistiocytosis
What to watch next
- Completion of Kyverna's rolling biologics license application in Q4 2026
- Further updates on Novartis' autoimmune CAR-T trials
- Kyverna's potential FDA approval and market launch
confidence 85%Sources used for this update (5)
- www.quiverquant.com — Kyverna Therapeutics Reports Durable Clinical Benefit and CNS Penetration With Miv-Cel in Progressive Multiple Sclerosis
- finance.yahoo.com — Kyverna Therapeutics Presents Full One-Year Registrational ...
- biotechreporter.news — Kyverna Therapeutics (Nasdaq:KYTX) Announces One-Year ...
- www.rttnews.com — Kyverna's Miv-cel Shows 49% Walking Improvement At One Year ...
- www.prnewswire.com — CAR T-Cell Therapy Shows Lasting Improvements in Stiff Person ...
-
Kyverna Reports Positive One-Year miv-cel Data Amid Autoimmune CAR-T Safety Concerns
Kyverna Therapeutics presented one-year results from its KYSA-8 registrational trial for stiff person syndrome and updated Phase 1 data for progressive multiple sclerosis at MSToronto2026. The data shows sustained clinical benefit and a safety profile lacking high-grade cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or immune effector cell-associated hemophagocytic lymphohistiocytosis. This performance contrasts with safety setbacks in the broader autoimmune CAR-T field, including three deaths in Novartis trials. Kyverna is now finalizing a rolling biologics license application for completion in the fourth quarter of 2026.
Why it matters
CAR T-cell therapies aim to induce deep remission by resetting the immune system in autoimmune patients. Recent trial pauses across the industry have raised questions regarding patient selection and risk tolerance. Kyverna's results provide a potential benchmark for safety in this therapeutic class.
What is confirmed
- Kyverna presented data for stiff person syndrome and progressive multiple sclerosis at MSToronto2026.
- The KYSA-8 registrational trial for stiff person syndrome showed sustained clinical benefit at one year.
- Kyverna reported no high-grade cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or immune effector cell-associated hemophagocytic lymphohistiocytosis in its latest data.
- Novartis experienced three deaths in its autoimmune CAR T-cell therapy trials.
- Kyverna expects to complete its rolling biologics license application in the fourth quarter of 2026.
What to watch next
- Completion of the rolling biologics license application in Q4 2026
- Regulatory decisions on the miv-cel application
- Further safety data from Novartis autoimmune trials
confidence 100%Sources used for this update (3)
- www.marketscreener.com — Latest news about Kyverna Therapeutics, Inc. - MarketScreener
- www.nature.com — A reality check for autoimmune CAR T cells | Nature Medicine
- www.finanznachrichten.de — KYVERNA THERAPEUTICS AKTIEN News | A402W6 Nachrichten
-
Kyverna Presents One-Year Data for Miv-Cel in Autoimmune Trials
Kyverna Therapeutics reported one-year results from the KYSA-8 registrational trial in stiff person syndrome and updated Phase 1 data in progressive multiple sclerosis at MSToronto2026. The findings demonstrate sustained clinical benefit and a well-tolerated safety profile without high-grade cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or immune effector cell-associated hemophagocytic lymphohistiocytosis. These results arrive as competitors face safety hurdles, including three deaths in autoimmune trials for Novartis' CAR T-cell therapy. Kyverna advances its rolling biologics license application toward completion in the fourth quarter of 2026.
Why it matters
The new safety data arrive while the broader field of autoimmune CAR-T treatments faces scrutiny following patient deaths in competing trials. Kyverna is positioning miv-cel to capture a first-to-market advantage for severe neurologic autoimmune conditions lacking approved therapies. The company is presenting these findings at MSToronto2026.
What is confirmed
- Full one-year results from the KYSA-8 registrational trial in stiff person syndrome demonstrate sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS.
- Updated Phase 1 investigator-initiated trial data in progressive multiple sclerosis highlight encouraging clinical activity and a well-tolerated safety profile.
- Novartis experienced three deaths in autoimmune trials for its CAR T-cell therapy.
- Kyverna is advancing its rolling BLA for miv-cel toward completion in the fourth quarter of 2026.
What to watch next
- Completion of Kyverna's rolling BLA for miv-cel in the fourth quarter of 2026
- Regulatory and commercialization updates for miv-cel in treating neurologic autoimmune conditions
confidence 95%Sources used for this update (6)
- finance.yahoo.com — Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
- www.biospace.com — Weighing the risks of CAR T in autoimmune disease as Kyverna ...
- www.biospace.com — CAR-T - BioSpace
- www.marketscreener.com — Kyverna Therapeutics, Inc.: Official Announcements - Stock ...
- markets.financialcontent.com — Pittsburgh Post-Gazette - Kyverna Therapeutics to Present ...
- briefglance.com — Kyverna Therapeutics Reports Positive Data for Stiff Person ...
-
Kyverna Advances Miv-Cel Toward BLA Completion
Kyverna Therapeutics is advancing its rolling BLA for miv-cel toward completion in the fourth quarter of 2026. New durability data show that patients with myasthenia gravis and stiff person syndrome sustained clinical benefits for over a year and remained off other autoimmune drugs following a single dose of the single-dose CD19 CAR T-cell therapy. These findings arrive as competing autoimmune CAR-T treatments encounter safety hurdles, positioning Kyverna to potentially capture a first-to-market advantage in treating severe neurologic autoimmune conditions with no currently approved therapies.
Why it matters
Kyverna is positioning miv-cel to meet urgent medical needs in rare neurologic conditions where treatment options remain limited. The ability of a single dose to maintain patient stability and eliminate the need for additional drugs represents a significant therapeutic milestone. This clinical progress arrives as rival developers navigate safety setbacks in the autoimmune cell-therapy sector.
What is confirmed
- Kyverna Therapeutics is developing miv-cel as a single-dose CD19 CAR T-cell therapy for neurologic autoimmune diseases.
- Patients with myasthenia gravis experienced improvements lasting more than one year following miv-cel treatment.
- New durability data demonstrates that patients stay off other autoimmune drugs after receiving a single cell-therapy dose.
Still unconfirmed
- The rolling BLA for miv-cel is scheduled for completion in the fourth quarter of 2026.
What to watch next
- Completion of the rolling BLA in the fourth quarter of 2026
- Regulatory updates regarding FDA approval for stiff person syndrome
- Further safety and durability readouts from autoimmune CAR-T competitors
confidence 90%Sources used for this update (3)
- www.thepharmaletter.com — Kyverna Therapeutics | The Pharma Letter | The Pharmaletter
- www.rarediseaseadvisor.com — Miv-cel Benefits Sustained for Up to 1.5 Years in MG
- biotech-insider.com — Kyverna's Cell Therapy Keeps Autoimmune Patients Off Other…
-
Kyverna Reports One-Year Miv-Cel Data for Stiff Person Syndrome
Kyverna Therapeutics released one-year clinical data for its CAR-T therapy, miv-cel, demonstrating durable efficacy and improved mobility in patients with stiff person syndrome. There are currently no FDA-approved drugs for stiff person syndrome, positioning Kyverna to secure a potential first-to-market advantage. The company is advancing its rolling FDA filing toward completion, aiming to establish a new benchmark for autoimmune CAR-T treatments addressing severe unmet medical needs in rare neurologic conditions.
Why it matters
Kyverna is positioning miv-cel at the forefront of CAR-T cell therapy innovation for autoimmune diseases. The one-year data release strengthens the company regulatory strategy as it moves closer to completing its FDA submission.
What is confirmed
- Kyverna Therapeutics reported one-year clinical data supporting its rare autoimmune CAR-T program, miv-cel, in stiff person syndrome.
- There are no FDA-approved drugs for stiff person syndrome, with Kyverna hoping to gain a first-to-market advantage for miv-cel.
- Kyverna Therapeutics' miv-cel demonstrated improved mobility and favorable safety at one year in stiff person syndrome patients.
- Kyverna Therapeutics is advancing its rolling FDA filing toward completion following durable one-year miv-cel results.
Still unconfirmed
- The favorable safety profile and durable efficacy results could set a new benchmark for autoimmune CAR T treatments addressing significant unmet needs in SPS and gMG.
What to watch next
- Completion of the rolling FDA filing for miv-cel
- Regulatory decisions regarding the first FDA-approved CAR-T therapy for an autoimmune condition
confidence 100%Sources used for this update (5)
- biobriefs.com — Autoimmune CAR-T: Kyverna reports one-year miv-cel data
- www.clinicaltrialsarena.com — Kyverna’s stiff-person syndrome trial shows one-year durability
- briefglance.com — Kyverna's Miv-cel Shows Durable Efficacy in Rare Neurologic ...
- catalystalert.io — Kyverna steps closer to FDA-first CAR T for an autoimmune ...
- business-news-today.com — Kyverna Therapeutics targets autoimmune CAR T breakthrough ...
-
Kyverna reports one-year durability for miv-cel in autoimmune trials
Kyverna Therapeutics has released one-year data for its CAR-T therapy, miv-cel, demonstrating drug-free remission and a strong safety profile in patients with generalized Myasthenia Gravis (gMG) and Stiff Person Syndrome (SPS). The company intends to use this long-term durability data to support its FDA submission. Kyverna aims to complete a Biologics License Application (BLA) for the treatment of Stiff Person Syndrome within the current year, positioning itself to potentially secure the first FDA-approved CAR-T therapy for an autoimmune condition.
Why it matters
CAR-T therapies were originally developed for oncology but are being adapted for autoimmune diseases. Recent safety issues encountered by other companies in the autoimmune CAR-T space make Kyverna's safety and durability data a critical benchmark for the field.
What is confirmed
- Miv-cel demonstrated durable, drug-free remission and strong safety in patients with SPS and gMG at one year.
- Kyverna is using long-term data to bolster its FDA submission for a rare autoimmune CAR-T therapy.
Still unconfirmed
- Kyverna is targeting a complete BLA submission for its Stiff Person Syndrome therapy this year.
- Kyverna is attempting to reset the industry conversation as peers encounter safety snags.
What to watch next
- Formal filing of the BLA for Stiff Person Syndrome
- FDA response to the miv-cel durability data
- Comparison of miv-cel safety profiles against competing autoimmune CAR-T candidates
confidence 90%Sources used for this update (6)
- Fierce Biotech — Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
- Endpoints News — Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
- STAT — Kyverna’s cell therapy shows lasting autoimmune benefit
- BioSpace — Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
- TradingView — KYTX: Miv-cel delivers durable, drug-free remission and strong safety in SPS and gMG at 1 year
- genomeweb.com — Kyverna Shooting for Complete BLA Submission for Stiff Person Syndrome CAR T-Cell Therapy This Year
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community